Research programme: meningococcal vaccine - IMV/National Research Council Canada
Latest Information Update: 17 May 2018
At a glance
- Originator Immunovaccine; National Research Council Canada
- Developer IMV; National Research Council Canada
- Class Bacterial vaccines; Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer; Meningococcal infections
Most Recent Events
- 03 May 2018 Immunovaccine is now called IMV
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Canada
- 16 Jul 2016 No recent reports of development identified for preclinical development in Meningococcal-infections in Canada